Sustained delivery of gambogic acid from mesoporous rod-structure hydroxyapatite for efficient in vitro cancer therapy

Biomater Adv. 2022 Jun:137:212821. doi: 10.1016/j.bioadv.2022.212821. Epub 2022 Apr 23.

Abstract

Inspired by the critical role of nanocarrier in biomaterials modification, we synthesized a mesoporous rod-structure hydroxyapatite (MR-HAp) nanoparticles for boosting gambogic acid (GA) bioavailability in cells and improving the tumor therapy. As expected, the GA loading ratio of MR-HAp was up to about 96.97% and GA-loaded MR-HAp (MR-HAp/GA) demonstrates a sustained release performance. Furthermore, a substantial improvement was observed in inhibiting the cell proliferation and inducing the apoptosis of HeLa cells, as the cell viability was decreased to 89.6% and the apoptosis was increased to 49.2% when the cells treated with MR-HAp/GA at a GA concentration of 1 μg/mL for 72 h. The remarkable inhibition effect of cell proliferation and the enhanced inducing apoptosis are attributed to the increasing intracellular reactive oxygen species level and reduced mitochondrial membrane potential. This result provides a promising and facile approach for highly efficient tumor treatment.

Keywords: Gambogic acid; HeLa cell; Hydroxyapatite; Mitochondrial membrane potential; Reactive oxygen species.

MeSH terms

  • Cell Line, Tumor
  • Durapatite / pharmacology
  • HeLa Cells
  • Humans
  • Neoplasms* / drug therapy
  • Xanthones* / pharmacology

Substances

  • Xanthones
  • gambogic acid
  • Durapatite